This study assessed whether the pre-treatment serum levels of hepcidin are a predictive factor of the overall survival of patients with microsatellite stable metastatic colorectal cancer receiving first-line treatment with FOLFOX-panitumumab (RAS/BRAF wild-type) or FOLFOX-bevacizumab (RAS or BRAF mutations). Here, BRAF is linked to metastatic colorectal cancer.